CA3248484A1 - TRIAZINE COMPOUND, INTERMEDIATE THEREOF, ASSOCIATED PREPARATION PROCESS AND CORRESPONDING USE - Google Patents
TRIAZINE COMPOUND, INTERMEDIATE THEREOF, ASSOCIATED PREPARATION PROCESS AND CORRESPONDING USEInfo
- Publication number
- CA3248484A1 CA3248484A1 CA3248484A CA3248484A CA3248484A1 CA 3248484 A1 CA3248484 A1 CA 3248484A1 CA 3248484 A CA3248484 A CA 3248484A CA 3248484 A CA3248484 A CA 3248484A CA 3248484 A1 CA3248484 A1 CA 3248484A1
- Authority
- CA
- Canada
- Prior art keywords
- hydrogen
- alkyl
- methyl
- formula
- butyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/08—Acetic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210245736 | 2022-03-10 | ||
| CN202210245736.X | 2022-03-10 | ||
| CN202210557410 | 2022-05-20 | ||
| CN202210557410.0 | 2022-05-20 | ||
| PCT/CN2023/080920 WO2023169572A1 (zh) | 2022-03-10 | 2023-03-10 | 一种三嗪类化合物、其中间体、其制备方法及其用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3248484A1 true CA3248484A1 (en) | 2025-07-07 |
Family
ID=87905051
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3248484A Pending CA3248484A1 (en) | 2022-03-10 | 2023-03-10 | TRIAZINE COMPOUND, INTERMEDIATE THEREOF, ASSOCIATED PREPARATION PROCESS AND CORRESPONDING USE |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250188102A1 (enExample) |
| EP (1) | EP4491623A4 (enExample) |
| JP (1) | JP2025510603A (enExample) |
| KR (1) | KR20250002216A (enExample) |
| CN (1) | CN116730988A (enExample) |
| AU (1) | AU2023231321A1 (enExample) |
| CA (1) | CA3248484A1 (enExample) |
| WO (1) | WO2023169572A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3224494A1 (en) | 2021-07-09 | 2023-01-12 | Koen Vandyck | Anti-viral compounds |
| CN116284133B (zh) * | 2022-03-24 | 2024-03-29 | 南京知和医药科技有限公司 | 一种新型六元杂环类衍生物及其药物组合物和用途 |
| CN116514784A (zh) * | 2022-04-01 | 2023-08-01 | 深圳安泰维生物医药有限公司 | 一种三嗪类化合物及其用途 |
| KR20250046274A (ko) | 2022-08-05 | 2025-04-02 | 길리애드 사이언시즈, 인코포레이티드 | SARS-CoV2 주요 프로테아제 억제제 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2604595T3 (pl) * | 2010-08-10 | 2016-09-30 | Pochodna triazyny i związek farmaceutyczny, który ją zawiera i wykazuje aktywność przeciwbólową | |
| CN114539228A (zh) * | 2022-03-14 | 2022-05-27 | 药康众拓(江苏)医药科技有限公司 | 三嗪类化合物或其可药用盐、异构体、药物组合物和用途 |
| CN114507221B (zh) * | 2022-04-21 | 2022-08-26 | 药康众拓(江苏)医药科技有限公司 | 一种三嗪类化合物及其在制备抗病毒药物上的用途 |
| CN114790198B (zh) * | 2022-06-24 | 2022-10-04 | 药康众拓(江苏)医药科技有限公司 | 一种三嗪类化合物及其制备方法和应用 |
| CN116496266A (zh) * | 2022-07-08 | 2023-07-28 | 歌礼生物科技（杭州）有限公司 | 三嗪衍生物 |
-
2023
- 2023-03-10 CN CN202310232863.0A patent/CN116730988A/zh active Pending
- 2023-03-10 KR KR1020247033807A patent/KR20250002216A/ko active Pending
- 2023-03-10 WO PCT/CN2023/080920 patent/WO2023169572A1/zh not_active Ceased
- 2023-03-10 JP JP2024554171A patent/JP2025510603A/ja active Pending
- 2023-03-10 EP EP23766149.1A patent/EP4491623A4/en active Pending
- 2023-03-10 US US18/845,444 patent/US20250188102A1/en active Pending
- 2023-03-10 AU AU2023231321A patent/AU2023231321A1/en active Pending
- 2023-03-10 CA CA3248484A patent/CA3248484A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20250002216A (ko) | 2025-01-07 |
| JP2025510603A (ja) | 2025-04-15 |
| CN116730988A (zh) | 2023-09-12 |
| AU2023231321A1 (en) | 2024-10-31 |
| EP4491623A1 (en) | 2025-01-15 |
| US20250188102A1 (en) | 2025-06-12 |
| EP4491623A4 (en) | 2026-03-18 |
| WO2023169572A1 (zh) | 2023-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4491623A1 (en) | Triazine compound, intermediate thereof, preparation method therefor and use thereof | |
| JP6666263B2 (ja) | グルタミナーゼの新規阻害剤 | |
| AU2018203354B2 (en) | Hepatitis B antiviral agents | |
| TWI753918B (zh) | 作為ｊａｋ抑制劑的吡咯並嘧啶化合物的結晶 | |
| KR102194646B1 (ko) | 암 치료를 위한 피리미딘-2,4-다이아민 유도체 | |
| TW202144345A (zh) | Ｋｒａｓ突變蛋白抑制劑 | |
| JP7728287B2 (ja) | Ｃｄｋ６／ｄｙｒｋ２二重標的阻害剤およびその製造方法と応用 | |
| WO2023042879A1 (ja) | ウイルス増殖阻害活性を有する二環性複素環誘導体およびそれらを含有する医薬組成物 | |
| CN1446217A (zh) | 用作磷酸二酯酶抑制剂的β－咔啉衍生物 | |
| CN112979679B (zh) | 具有大环结构的含氟并杂环衍生物及其用途 | |
| JP2020526569A (ja) | 環内チアミジノアミド−アリールアミド系化合物及びｂ型肝炎を治療するためのその用途 | |
| CN117337290A (zh) | 三并环类泛素特异性蛋白酶1抑制剂及其用途 | |
| JP6855636B2 (ja) | イミダゾリジン化合物 | |
| TW200304824A (en) | Nicotinamide derivatives useful as PDE4 inhibitors | |
| US6608058B2 (en) | 6-methylnicotinamide derivatives as antiviral agents | |
| JP2024512753A (ja) | 新規なジアルコキシナフト［２，３－ｃ］フラン－１（３Ｈ）－オン誘導体およびこれを含む呼吸器疾患またはＳＡＲＳ－ＣｏＶ－２感染症の予防または治療用の薬学的組成物 | |
| JP2024125432A (ja) | 抗マラリア活性を有するキノロン誘導体 | |
| EP3964509A1 (en) | Compound containing fused ring, use thereof and pharmaceutical composition containing same | |
| CN117120423B (zh) | 吲哚胺2,3-双加氧酶抑制剂、其制备方法及包含其的药物组合物 | |
| WO2025074997A1 (ja) | ウイルス増殖阻害活性を有する縮合複素環誘導体およびそれらを含有する医薬組成物 | |
| JP2003523952A (ja) | 新規な３−ニトロピリジン誘導体及び該誘導体を含む製薬組成物 | |
| WO2022218239A1 (zh) | 新型噻唑类化合物及其制备方法和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20241010 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20241105 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241105 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241105 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20241120 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250227 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250227 |
|
| Q12 | Application published |
Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION PUBLISHED (OPEN TO PUBLIC INSPECTION) Effective date: 20250707 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260127 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260127 |